1887

n Southern African Journal of HIV Medicine - Why it's time to say goodbye to stavudine ... everywhere : debate

Volume 13, Issue 1
  • ISSN : 1608-9693
USD

 

Abstract

: The previous issue of the (December 2011) carried an Opinion piece by Innes, Cotton and Venter regarding the potential value of low-dose of stavudine (20 mg twice a day). They suggested that reduced dosing of stavudine may lead to levels of viral suppression comparable with those achieved with stavudine 30 mg bd but with a lower risk of toxicity and side-effects, and at a fraction of the cost of tenofovir. The Opinion was related to a larger proposal, led by Venter, to conduct a head-to-head trial comparing low-dose stavudine with tenofovir (both in a regimen including lamivudine and efavirenz) on viral suppression and other treatment outcomes over 24 months. There has been considerable debate regarding the advantages and disadvantages of low-dose stavudine, and in turn the value of any such trial. Here the debate continues with a commentary by Isabelle Andrieux-Meyer . and a rebuttal by Venter and colleagues.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/m_sajhiv/13/1/EJC65597
2012-03-01
2016-12-11

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error